Immuno-Oncology | Video | Real-world usage of immune checkpoint inhibitors - ESMO 2024
Learn first-hand how oncologists are generating collaborative scientific value through the granular precision data unlocked by LynxCare.
With thanks to Medimix and Dr. Annelies Verbiest (UZA).
With multi-use hospital databases capturing comprehensive oncology data, we empower physicians and researchers to drive impactful research, accelerate insights across the full cancer patient journey, and fuel meaningful evidence-based innovation in cancer therapies.
Listen to Dr. Annelies Verbiest (UZA) as she shares the first findings of our joint multi-center study into immune checkpoint inhibitor (ICI) treatment patterns across 1,574 real-world cancer patients in three Belgian hospitals.
With multi-use hospital databases capturing comprehensive oncology data, we empower physicians and researchers to drive impactful research, accelerate insights across the full cancer patient journey, and fuel meaningful evidence-based innovation in cancer therapies.
Listen to Dr. Annelies Verbiest (UZA) as she shares the first findings of our joint multi-center study into immune checkpoint inhibitor (ICI) treatment patterns across 1,574 real-world cancer patients in three Belgian hospitals.
